Citations

Clear

2303 citation(s) found for "Yu, Edward".

Abstract IS04: PARP INHIBITOR COMBINATIONS FOR THE TREATMENT OF OVARIAN CANCER
Hendrickson, Andrea E. Wahner , Harrell, Maria I., Menefee, Michael E., Karnitz, Larry M., Kaufmann, Scott H. , Tanner, Edward J. , Mutch, David G. , Swisher, Elizabeth M.

Mayo Clinic

Clinical Cancer Research | June 6, 2017 | Volume: 23 | Issue: 11_Supplement | Pages: IS04-IS04

10.1158/1557-3265.ovcasymp16-is04 Get It

Abstract Poly(ADP-ribose) polymerase (PARP) inhibitors have shown promising single-agent activity in ovarian cancers with BRCA1 and BRCA2 mutations (C. Scott, JCO 33:1397, 2015). Ongoing studies are testing the efficacy of PARP inhibitors in ovarian cancers with other genetic or epigenetic alterations that impair the homologous recombination (HR) pathway of DNA repair. It is less clear whether PARP inhibitor clinical activity can be enhanced in HR deficient cancers or even extended to HR proficient ovarian cancers through judicious combinations. Our preclinical studies have demonstrated that PARP inhibitors enhance the cytotoxic effects of selected therapeutic agents through a variety of mechanisms: By trapping PARP at sites of DNA damage, PARP inhibitors enhance the cytotoxicity of topotecan (A. Patel, J. Biol. Chem. 287: 4198, 2012).By inhibiting base excision repair, PARP inhibitors enhance the cytotoxicity of floxuridine (A. Huehls, Cancer Res. 71: 4944, 2011), an agent previously shown to have clinical activity in ovarian cancer. Building on the first of these observations, we conducted a phase 1 clinical trial of topotecan weekly x 3 in combination with veliparib (NCT01012817). Using a standard 3+3 design, patients were treated with veliparib PO twice daily on days 1-3, 8-10 and 15-17 and topotecan IV on days 2, 9 and 16 every 28 days. The dose-limiting toxicity was neutropenia. The MTD was veliparib 300 mg PO twice daily and topotecan 3 mg/m2/dose. Among 52 evaluable patients, objective responses (1 CR, 3 PRs) and stable disease (22 patients, 6 lasting ≥ 8 cycles) were observed. While there was no clear correlation between germline BRCA1 or BRCA2 mutations and clinical benefit, a patient with a germline RAD51D mutation had stable disease for 14 cycles. A phase 2 cohort in platinum-resistant ovarian cancer has just opened. Building on the second set of preclinical observations, we are also conducting a phase 1 trial of veliparib and IP floxuridine in patients with recurrent ovarian cancer confined to the peritoneal cavity (NCT01749397). Using a rolling 6 design, patients are treated with veliparib PO twice daily on days 1-10 and floxuridine IP on days 3-5 every 21 days. The trial is currently enrolling at dose level 5 (veliparib 300 mg PO twice daily on days 1-10 and floxuridine 3 gm/dose IP on days 3-5). Grade 3 toxicities in any cycle have included nausea (1), fatigue (1) and neutropenia (3). Among 20 evaluable patients, treatment duration has ranged from 2-33 cycles. These studies, which build on two different aspects of PARP1 function, illustrate two different approaches to potentially enhancing the activity of PARP inhibitors in relapsed ovarian cancer. These studies were funded in part by NIH grants P50 CA136393, R01 CA190423, and UM1 CA186686 as well as SU2C-AACR DT16-15. Citation Format: Scott H. Kaufmann, Andrea E. Wahner Hendrickson, Maria I Harrell, Michael E. Menefee, Edward J. Tanner, David G, Mutch, Elizabeth M. Swisher, and Larry M. Karnitz. PARP INHIBITOR COMBINATIONS FOR THE TREATMENT OF OVARIAN CANCER [abstract]. In: Proceedings of the 11th Biennial Ovarian Cancer Research Symposium; Sep 12-13, 2016; Seattle, WA. Philadelphia (PA): AACR; Clin Cancer Res 2017;23(11 Suppl):Abstract nr IS04.
Cholesterol uptake and regulation in high-grade and lethal prostate cancers
Stopsack, Konrad H. , Gerke, Travis , Andrén, Ove, Andersson, Swen‐Olof, Giovannucci, Edward L. , Mucci, Lorelei A. , Rider, Jennifer R. , Gerke, Travis A, Stopsack, Konrad H

Mayo Clinic

Carcinogenesis | June 6, 2017 | Volume: 38 | Issue: 8 | Pages: 806-811

10.1093/carcin/bgx058 | PMID 28595267 Get It

Cervicomedullary compression as the main manifestation of wild-type transthyretin amyloidosis
Rezania, Kourosh , Pytel, Peter , Highsmith, W. Edward, Gabikian, Patrik

Mayo Clinic

Amyloid | May 23, 2017 | Volume: 24 | Issue: 2 | Pages: 133-134

10.1080/13506129.2017.1331907 | PMID 28532173 Get It

Repeatability of MR Elastography of Liver: A Meta-Analysis
Serai, Suraj D. , Obuchowski, Nancy A. , Venkatesh, Sudhakar K. , Miller, Frank H. , Ashton, Edward, Cole, Patricia E., Sirlin, Claude B. , Ehman, Richard L. , Venkatesh, Sudhakar K , Serai, Suraj D , Miller, Frank H

Mayo Clinic

Radiology | May 22, 2017 | Volume: 285 | Issue: 1 | Pages: 92-100

10.1148/radiol.2017161398 | PMID 28530847 Get It

Guidelines for Family-Centered Care in Neuro-ICU Populations: Caveats for Routine Palliative Care
Torbey, Michel , Brophy, Gretchen M. , Varelas, Panayiotis N. , Bösel, Julian , Manno, Edward M., Suárez, José I. , Seder, David B. , Freeman, William D. , Torbey, Michel T, Bader, Mary Kay , Freeman, William D , Brophy, Gretchen M

Mayo Clinic

Critical Care Medicine | May 17, 2017 | Volume: 45 | Issue: 6 | Pages: e620-e621

10.1097/ccm.0000000000002344 | PMID 28509746 Get It

A joint procedural position statement on imaging in cardiac sarcoidosis: from the Cardiovascular and Inflammation & Infection Committees of the European Association of Nuclear Medicine, the European Association of Cardiovascular Imaging, and the Americ
group:, Writing, Glaudemans, Andor W.J.M. , Lancellotti, Patrizio , Hyafil, Fabien , Blankstein, Ron, Schwartz, Ronald G. , Russell, Raymond R., Gimelli, Alessia , Rouzet, François , Hacker, Marcus , Plein, Sven , group:, Document reading, Sciagrà, Roberto , Bucerius, Jan , Verberne, Hein J. , Lindner, Oliver , Übleis, Christopher, Agostini, Denis, Signore, Alberto , Edvardsen, Thor , Neglia, Danilo , Beanlands, Rob , Carli, Marcelo F. Di , Dilsizian, Vasken , Habib, Gilbert, Delgado, Victoria , Cosyns, Bernard, Flachskampf, Frank A. , Gerber, Bernhard , Haugaa, Kristina H. , Lombardi, Massimo, Slart, Riemer H. J. A. , Blankstein, Ron , Jaber, Wael A. , Gheysens, Olivier S. , Miller, Edward J. , Dorbala, Sharmila , Donal, Erwan , Chareonthaitawee, Panithaya , Soman, Prem , Habib, G., Cardim, Nuno Miguel , Masci, Pier Giorgio , Delgado, Victoria , Plein, Sven , Haugaa, Kristina , Neglia, Danilo

Mayo Clinic

European Heart Journal - Cardiovascular Imaging | May 16, 2017 | Volume: 18 | Issue: 10 | Pages: 1073-1089

10.1093/ehjci/jex146 | PMID 28984894 Get It

Abstract This joint position paper illustrates the role and the correct use of echocardiography, radionuclide imaging with 18F-fluorodeoxyglucose positron emission tomography, radionuclide myocardial perfusion imaging and cardiovascular magnetic resonance imaging for the evaluation and management of patients with known or suspected cardiac sarcoidosis. This position paper will aid in standardizing imaging for cardiac sarcoidosis and may facilitate clinical trials and pooling of multi-centre data on cardiac sarcoidosis. Proposed flow charts for the work up and management of cardiac sarcoidosis are included.
Immune modulator therapy for microscopic colitis in a case series of 73 patients
Cotter, Thomas G. , Kamboj, Amrit K. , Hicks, Stephen B., Tremaine, William J., Loftus, Edward V. , Pardi, Darrell S. , Cotter, T G , Loftus, Edward V

Mayo Clinic

Alimentary Pharmacology & Therapeutics | May 10, 2017 | Volume: 46 | Issue: 2 | Pages: 169-174

10.1111/apt.14133 | PMID 28488312 Get It

SummaryBackgroundMicroscopic colitis (MC) is a common cause of chronic diarrhoea. Various treatment options have been described, but there are limited data describing outcomes of corticosteroid‐sparing treatments.AimTo evaluate the outcomes of patients with active MC treated with immune modulators.MethodsAll patients seen at Mayo Clinic, Rochester between January 1, 1997 and November 30, 2016 with a histological diagnosis of MC were identified. Patients treated with an immune modulator of interest were selected and clinical outcomes recorded.ResultsSeventy‐three MC patients (50 collagenous colitis and 23 lymphocytic colitis) with a median disease duration of 24 months (range, 7‐60) were included. The indications for treatment were budesonide‐refractoriness in 66%, budesonide dependence in 29%, and budesonide intolerance in 5%. Median age was 51.8 years (range, 43.4‐63.1) and 61 (84%) were female. Thiopurines were used in 49 patients (67%) for a median of 4 months (range, 1.5‐15). Complete and partial response occurred in 43% and 22% respectively. Adverse effects resulting in therapy cessation occurred in 17 patients (35%). Twelve patients (16%) were treated with methotrexate for a median of 14 months (3‐18.8). Complete and partial response occurred in 58% and 17%, respectively. Anti‐TNF therapy was used in 10 patients (14%) for a median of 4 months (range, 2.3‐5.5). Complete response occurred in four patients and partial response in four patients.ConclusionsThe majority of patients with active MC responded to thiopurines, methotrexate, or anti‐TNF therapy. Larger controlled studies are required to confirm the efficacy and safety of these medications in MC.
Differentiating pulmonary transfusion reactions using recipient and transfusion factors
Looney, Mark R. , Keating, Sheila M. , Kor, Daryl J. , Lowell, Clifford A. , Hubmayr, Rolf D., Gropper, Michael A. , Koenigsberg, Monique, Wilson, Gregory , Matthay, Michael A. , Toy, Pearl, Murphy, Edward L. , Group, the TRALI Study, Hubmayr, Rolf, Wilson, Gregory A, Roubinian, Nareg H. , Gajic, Ognjen , Group, the TRALI Study

Mayo Clinic

Transfusion | May 4, 2017 | Volume: 57 | Issue: 7 | Pages: 1684-1690

10.1111/trf.14118 | PMID 28470756 Get It

BACKGROUNDIt is increasingly recognized that recipient risk factors play a prominent role in possible transfusion‐related acute lung injury (pTRALI) and transfusion‐associated circulatory overload (TACO). We hypothesized that both transfusion and recipient factors including natriuretic peptides could be used to distinguish TRALI from TACO and pTRALI.STUDY DESIGN AND METHODSWe performed a post hoc analysis of a case‐control study of pulmonary transfusion reactions conducted at the University of California at San Francisco and Mayo Clinic, Rochester. We evaluated clinical data and brain natriuretic peptides (BNP) levels drawn after transfusion in patients with TRALI (n = 21), pTRALI (n = 26), TACO (n = 22), and controls (n = 24). Logistic regression and receiver operating characteristics curve analyses were used to determine the accuracy of clinical and biomarker predictors in differentiating TRALI from TACO and pTRALI.RESULTSWe found that pTRALI and TACO were associated with older age, higher fluid balance, and elevated BNP levels relative to those of controls and TRALI. The following variables were useful in distinguishing cases of pTRALI and TACO from TRALI: age more than 70 years, BNP levels more than 1000 pg/mL, 24‐hour fluid balance of more than 3 L, and a lower number of transfused blood components. Using the above variables, our logistic model had a 91% negative predictive value in the differential diagnosis of TRALI.CONCLUSIONSModels incorporating readily available clinical and biomarker data can be used to differentiate transfusion‐related respiratory complications. Additional studies examining recipient risk factors and the likelihood of TRALI may be useful in decision making regarding donor white blood cell antibody testing.